New Jersey, USA-based Merck & Co (NYSE: MRK) has reported positive top-line data from a trial of its oral HIF-2α blocker Welireg (belzutifan).
In 2021, Welireg was approved in the USA for the treatment of von Hippel-Lindau (VHL) disease, a rare kidney condition, with quarterly sales growing to the low tens of millions.
Merck is running the LITESPARK-005 trial with the goal of expanding the label to include the treatment of advanced renal cell carcinoma (RCC) as a later-line treatment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze